newswire, breaking biotechnology and pharma news

Tuesday, October 9, 2012

Biotech Stock News: Sunshine Biopharma (OTCBB: SBFM) Receives Scale-Up Manufacturing Protocol for Its Lead Anti-Cancer Compound, Adva-27a

MONTREAL - October 9, 2012 ( Newswire) Sunshine Biopharma Inc. (OTCBB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has received the Scale-Up Manufacturing Protocol from the Contract Manufacturing Organization (CMO) and is now poised to begin the process of manufacturing gram quantities of Adva-27a in preparation for conducting initial IND-Enabling studies. Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR). Initial or Pre-IND-Enabling studies include a variety of in vitro biological tests as well as studies in live rats and mice in order to ascertain that the scale-up manufacturing process generates a compound that is identical to the original used in the pre-clinical studies.

"We are very excited to be at the scale-up stage and have the capacity to manufacture gram quantities of our Adva-27a compound," said Mr. Camille Sebaaly, Sunshine Biopharma's CFO. "This is a very important milestone in our Adva-27a development program," he added.
About Sunshine Biopharma Inc. (OTCBB : SBFM ):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer (
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information
Camille Sebaaly
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
Published at newswire
Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/ Disclosure: The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:

No comments:

Post a Comment